Open AccessONCOLYTIC VIRAL THERAPY IN CANCER THERAPEUTICS
Author(s) -
Krishnan Vengadaragava Chary,
Anish S Bharatwaj
Publication year - 2017
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2017.v10i10.19265
Subject(s) - oncolytic virus , medicine , clinical trial , food and drug administration , observational study , oncology , virotherapy , cancer , drug , intensive care medicine , pharmacology
Objective: The aim of this study is to provide comprehensive information of oncolytic viral therapy, from the origin to present scenario.Methods: This observational study was conducted by the Department of Pharmacology, Saveetha Medical College, Chennai between July and December 2016. Date regarding ongoing oncolytic virotherapy trials was retrieved from clinical trial database, United States and Clinical trial registry forum, India. Tamilnogene approval details were obtained from the US-Food and Drug Administration approval new drug approval information.Results: Eleven ongoing trials in Phase I and Ia are being carried out, of which 4 viral strains such as herpes, adenovirus, measles, and reovirus are used for intracerebral malignancies. Four trials have shown superior effects and seven trial results are yet to be completed.Conclusion: Oncolytic viral therapy can be as effective as targeted therapy in battling against cancer; however, long-term efficacy and safety should be established from more studies and meta-analysis.